Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,599 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Skin Patch Clear all

Conditions: Parkinson's Disease
Interventions: ROTIGOTINE; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Long Beach, California • Hallandale, Florida • Atlanta, Georgia

Conditions: Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions: 17 B estradiol orally, 17 B estradiol; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 13 Years to 20 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Jacksonville, Florida • Philadelphia, Pennsylvania

Conditions: Spina Bifida
Interventions: Autologous umbilical cord patch; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Up to 24 Hours
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Arthritis, Osteo Arthritis of the Knee
Interventions: Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, Intra articular injection; Device · Drug
Lead sponsor: ZetrOZ, Inc.; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Stamford, Connecticut • Dryden, New York

Conditions: Tuberculosis
Interventions: Digital Health Feedback System, SOC DOT; Device · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: San Diego, California

Conditions: Pigmentation
Interventions: Dermal Cooling System; Device
Lead sponsor: R2 Dermatology; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Pleasanton, California

Conditions: Vital Signs, Pediatrics, Remote Monitoring
Interventions: Vitls Tego Device; Device
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: Up to 2 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Cardiogenic Shock, Acute Myocardial Infarction, Acute Decompensated Heart Failure
Interventions: NIRSense Tissue Oximetry Sensor System; Device
Lead sponsor: NIRSense Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Device Latency
Interventions: MIND1 System; Device
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Smoking Cessation
Interventions: Standard Care (SC), Intensive Counseling (IC); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: Effects of Heat, Tolerability, Adhesiveness, Dermal Irritation
Interventions: Thermal Adhesive Patch, Marketed Thermal Adhesive Patch, Placebo Patch; Device
Lead sponsor: Chattem, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Pinellas Park, Florida

Conditions: Smoking Cessation
Interventions: Standard Care, Precision pharmacotherapy; Behavioral
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Cigarette Smoking
Interventions: Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (0.07 mg), MCE-; Drug · Behavioral
Lead sponsor: Francis McClernon, Ph.D.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: lidocaine, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 159
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 95 more

Conditions: Restless Legs Syndrome
Interventions: Rotigotine, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Birmingham, Alabama • Jasper, Alabama • Gilbert, Arizona + 15 more

Conditions: Chlorhexidine Allergy, Infection, Rash
Interventions: Chlorhexidine gluconate; Drug
Lead sponsor: Celeste Chandonnet; Other
Eligibility: 36 Weeks to 48 Weeks
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Sarcoidosis
Interventions: nicotine patch; Drug
Lead sponsor: Elliott Crouser MD; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Smoking Cessation
Interventions: nicotine patch, experimental use, nicotine patch, labeled use; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 701 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD)
Interventions: Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm); Drug · Other
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 2 Years to 21 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: COPD
Interventions: Transcutaneous Electrical Muscle Stimulation (TCEMS), Sham TCEMS; Procedure · Other
Lead sponsor: Yale University; Other
Eligibility: Up to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Hypoactive Sexual Desire Disorder (HSDD)
Interventions: Testosterone Transdermal System, Placebo patch; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coronary Artery Disease
Interventions: Medical/Behavioral therapy, Standard of Care, Registry; Other
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia

Conditions: Cigarette Smoker, Tobacco Use Disorder
Interventions: Behavioral Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Smoking Cessation Intervention; Behavioral · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Suicide
Interventions: Transdermal Estradiol, Placebo; Drug · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism

Autologous Human Umbilical Cord Tissue Patch for Postnatal Closure of Open Neural Tube Defects

Long Duration High Frequency Ultrasound for the Treatment of Osteoarthritis

Wirelessly Observed Therapy in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis

Evaluation of the Dermal Cooling System for the Enhanced Treatment of Benign Pigmented Lesions and Common Skin Conditions

Vitls Feasibility Physiologic Monitoring

Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock

Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial

Evaluation of Experimental and Commercial Air-Activated, Adhesive Backed Heat Patches

Precision Pharmacotherapy Smoking Cessation Program

Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)

Lidocaine Patch in Treating Cancer Patients With Neuropathic Pain After Surgery

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age

Study of Nicotine Patches in Patients With Sarcoidosis

Treatment of Smoking Lapses and Relapses

Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis

Rehabilitation of Patients With COPD Using Electrical Muscle Stimulation

Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

The Precision CAD Trial

Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation

Neurocognitive Mechanisms of Perimenstrual Estrogen Effects on Suicidality